MAJOR SHAREHOLDERS 18 18.1 ALLOCATION OF SHARE CAPITAL 18.1.1 SHAREHOLDERS As of the date of this Registration Document, we are not The table below sets forth the non-diluted share capital structure, controlled by any majority shareholder and our share capital isbased on available information as of the date of this Registration equal to €605,855.58 divided into 24,234,223 fully authorized, Document. subscribed and paid-up ordinary shares with a nominal value of €0.025. Shareholders Number of shares/ % of share capital/ voting rights voting right (non-diluted) 5% Shareholders: Novartis Pharma AG 3,521,774 14.53% Versant 3,280,381 13.54% Abingworth Bioventures VI LP 3,139,973 (1) 12.96% Bpifrance Participations 2,000,000 8.25% Fidelity Management & Research Company 1,628,865 (2) 6.72% Vitavest S.à.r.l 1,339,706 5.53% Bpifrance Investissement 975,666 4.03% Directors and Executive Officers: Bernard Gilly 622,600 2.57% Thomas Gidoin 75,000 0.31% Barrett Katz — — Didier Pruneau (3) 100,880 0.42% Peter Goodfellow — — Michael Wyzga — — Simone Seiter — — Guido Magni — — Natalie Mount — — Charlotte Corbaz — — Employee Shareholding 193,000 0.80% Former employees 812,964 3.35% Other Shareholders (total) 6,543,414 27.00% TOTAL 24,234,223 100% (1) This amount does not include 1.60 partial shares resulting from the share split on September 3, 2015. (2) This amount does not include 6.80 partial shares resulting from the share split on September 3, 2015, as per public filing dated January 31, 2018. (3) Didier Pruneau retired on February 27, 2018. 176– GENSIGHT BIOLOGICS – 2017 Registration Document